The Effect of Thymopentin on Immune Function and Inflammatory Levels in End-stage Renal Disease Patients with Maintenance Hemodialysis

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2022 Feb 17

PMID 35173860

Authors

Qian Zou

Ling Zhang

Funyun Sun

Affiliations

Soon will be listed here.

Abstract

Objective: This study investigated and analyzed the effect of Thymopentin on immune function and inflammatory levels in end-stage renal disease (ESRD) patients who were undergoing maintenance hemodialysis.

Methods: A total of 112 patients with ESRD on regular hemodialysi from May 2018 to October 2019 were chosen and classified into an observation group and a control group by a convenience sampling method, with 56 cases in each group. The control-group was treated with conventional therapy, and the observation-group was treated with thymic pentapeptide based on the conventional treatment. The two groups' improvements in inflammation level, immunological functioning and living quality before and after treatment were compared.

Results: IL-6, IL-8, TNF-α, and hs-CRP levels in the observation group after treatment were (5.52±1.46) ng/L, (18.76±2.83) ng/L, (3.27±1.08) pmol/L and (24.12±2.96) mg/L respectively, which were lower than (6.68±1.51) ng/L, (24.12±2.96) ng/L, (5.13±1.15) pmol/L and (6.46±1.19) mg/L in the control group (t=4.133, 9.795, 8.828, 6.198; ). After treatment, SOD level in the observation-group was (115.52±9.46) u/mL, which was higher than that of (104.68±9.21) u/mL in the control group (=6.144, ); and MDA in the observation-group was (4.06±0.83) u/mL, which was lower than that of (5.22±0.96) u/mL in the control group (t=6.840, ). In addition, CD3 (68.25±12.54)%, CD4 (49.17±6.23)%, and CD4/CD8 (1.95±0.37) in the observation group during post-intervention were higher than of the counterparts (62.61±10.23)%, (45.21±5.89)% (1.71±0.32) in the control group (=2.608, 3.457, 4.807; ); while CD8 in the observation group (20.14±5.25)% was lower than that in the control group (25.01±5.47)% (=3.671; ). The SF-36 score in the observation group after treatment was (73.43±5.59) points, which was superior to the score (66.06±5.22) in the control group (=7.211, ).

Conclusion: Thymopentin can greatly improve the micro-inflammatory state of ESRD patients with maintenance hemodialysis, thereby improving the patient's immune function and living quality.

Citing Articles

Xinghamide A, a New Cyclic Nonapeptide Found in .

Um S, Lee J, Kim S, Cho K, Kang K, Kim S Mar Drugs. 2023; 21(10).

PMID: 37888444 PMC: 10608500. DOI: 10.3390/md21100509.

References

Shibiru T, Gudina E, Habte B, Derbew A, Agonafer T . Survival patterns of patients on maintenance hemodialysis for end stage renal disease in Ethiopia: summary of 91 cases. BMC Nephrol. 2013; 14:127. PMC: 3693969. DOI: 10.1186/1471-2369-14-127. View

Pai S, Chaikin P, Berg J . Pharmacokinetics of Lapatinib, a Nonrenally Cleared Drug, in Patients With End-Stage Renal Disease on Maintenance Hemodialysis. J Clin Pharmacol. 2019; 59(10):1379-1383. DOI: 10.1002/jcph.1430. View

Chen H, Wang Y, Qi R, Schoepf U, Varga-Szemes A, Ball B . Altered Amygdala Resting-State Functional Connectivity in Maintenance Hemodialysis End-Stage Renal Disease Patients with Depressive Mood. Mol Neurobiol. 2016; 54(3):2223-2233. DOI: 10.1007/s12035-016-9811-8. View

Nielsen T, Plesner L, Warming P, Pallisgaard J, Dalsgaard M, Schou M . YKL-40 in patients with end-stage renal disease receiving haemodialysis. Biomarkers. 2018; 23(4):357-363. DOI: 10.1080/1354750X.2018.1428359. View

Mandel-Shorer N, Tzvi-Behr S, Harvey E, Revel-Vilk S . Central venous catheter-related venous thrombosis in children with end-stage renal disease undergoing hemodialysis. Thromb Res. 2018; 172:150-157. DOI: 10.1016/j.thromres.2018.10.031. View

Nakamoto H, Kobayashi T, Noguchi T, Kusano T, Ashitani K, Imaeda H . Prevalence and Severity of Itching in Patients with End-Stage Renal Disease: Treatment with Nalfurafine Hydrochloride. Blood Purif. 2019; 47 Suppl 2:45-49. DOI: 10.1159/000496637. View

Minami Y, Kajimoto K, Sato N, Hagiwara N, Takano T . End-stage renal disease patients on chronic maintenance hemodialysis in a hospitalized acute heart failure cohort: Prevalence, clinical characteristics, therapeutic options, and mortality. Int J Cardiol. 2016; 224:267-270. DOI: 10.1016/j.ijcard.2016.09.038. View

Lu W, Ren C, Han X, Yang X, Cao Y, Huang B . The protective effect of different dialysis types on residual renal function in patients with maintenance hemodialysis: A systematic review and meta-analysis. Medicine (Baltimore). 2018; 97(37):e12325. PMC: 6156018. DOI: 10.1097/MD.0000000000012325. View

Konigsbrugge O, Lorenz M, Auinger M, Schmaldienst S, Klauser-Braun R, Kletzmayr J . Venous thromboembolism and vascular access thrombosis in patients with end-stage renal disease on maintenance hemodialysis: Cross-sectional results of the Vienna InVestigation of AtriaL fibrillation and thromboembolism in patients on hemoDIalysis.... Thromb Res. 2017; 158:59-64. DOI: 10.1016/j.thromres.2017.08.011. View

10.

Soltani P, Ketabi Moghaddam P, Haghverdi F, Cheraghi A . A Randomized Clinical Trial of the Effect of Pentoxifylline on C-Reactive Protein Level and Dialysis Adequacy in End-stage Renal Disease Patients on Maintenance Hemodialysis. Iran J Kidney Dis. 2016; 10(5):299-303. View

11.

Wang S, Zang X, Fu S, Bai J, Liu J, Tian L . Factors related to fatigue in Chinese patients with end-stage renal disease receiving maintenance hemodialysis: a multi-center cross-sectional study. Ren Fail. 2016; 38(3):442-50. DOI: 10.3109/0886022X.2016.1138819. View

12.

Tapolyai M, Faludi M, Berta K, Szarvas T, Lengvarszky Z, Molnar M . The effect of ambient temperature and humidity on interdialytic weight gains in end-stage renal disease patients on maintenance hemodialysis. Int Urol Nephrol. 2016; 48(7):1171-6. DOI: 10.1007/s11255-016-1297-9. View

13.

Santosh S, Chu C, Mwangi J, Narayan M, Mosman A, Nayak R . Changes in pulmonary artery systolic pressure and right ventricular function in patients with end-stage renal disease on maintenance dialysis. Nephrology (Carlton). 2017; 24(1):74-80. DOI: 10.1111/nep.13183. View

14.

Sexton D, Reule S, Solid C, Chen S, Collins A, Foley R . End-stage renal disease from hemolytic uremic syndrome in the United States, 1995-2010. Hemodial Int. 2015; 19(4):521-30. PMC: 4539282. DOI: 10.1111/hdi.12281. View

15.

Rivara M, Adams S, Kuttykrishnan S, Kalantar-Zadeh K, Arah O, Cheung A . Extended-hours hemodialysis is associated with lower mortality risk in patients with end-stage renal disease. Kidney Int. 2016; 90(6):1312-1320. PMC: 5123950. DOI: 10.1016/j.kint.2016.06.028. View

16.

Allawi A . Malnutrition, inflamation and atherosclerosis (MIA syndrome) in patients with end stage renal disease on maintenance hemodialysis (a single centre experience). Diabetes Metab Syndr. 2017; 12(2):91-97. DOI: 10.1016/j.dsx.2017.09.003. View

17.

El-Mashad G, Omar Z, Seif E . Evaluation of dialysis practice patterns in children having end-stage renal disease on maintenance hemodialysis at a pediatric nephrology unit. Saudi J Kidney Dis Transpl. 2019; 30(3):615-627. DOI: 10.4103/1319-2442.261334. View

18.

Nakao T, Kanazawa Y, Takahashi T . Once-weekly hemodialysis combined with low-protein and low-salt dietary treatment as a favorable therapeutic modality for selected patients with end-stage renal failure: a prospective observational study in Japanese patients. BMC Nephrol. 2018; 19(1):151. PMC: 6022443. DOI: 10.1186/s12882-018-0941-2. View

19.

Muller D, Goldstein S . Hemodialysis in children with end-stage renal disease. Nat Rev Nephrol. 2011; 7(11):650-8. DOI: 10.1038/nrneph.2011.124. View